IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
MOUNTAIN VIEW, Calif., April 19, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release financial results for the first quarter 2017 after the close of trading on Wednesday, May 3, 2017. The Company's management team will host a corresponding conference call beginning at 2:30 p.m. PT / 5:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 3...
MOUNTAIN VIEW, Calif., March 15, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the Sidoti & Co. Spring 2017 Convention in New York, NY.
Iridex's management is scheduled to present on Wednesday, March 29, 2017 at 3:00pm ET. Interested parties can access the live webcast at www.IRIDEX.com. An archived presentation will also be available on the Company's website.
Cyclo G6™ Glaucoma Laser Platform Fourth Quarter Revenue Up 67% Year-over-Year Record Revenue of $12.5 Million in the Fourth Quarter of 2016
MOUNTAIN VIEW, Calif., March 8, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the three months and full year ended December 31, 2016 and provided its full year 2017 financial outlook.
Fourth Quarter and 2016 Financial Highlights
Total revenue of $12.5 million for the...
The award winning CYCLO G6™ Glaucoma Laser System now offers a treatment with built-in transillumination
MOUNTAIN VIEW, Calif., Feb. 28, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) is pleased to announce the availability of the G-Probe™ Illuminate, a new, FDA-cleared probe offering combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC). The G-Probe Illuminate marks the third member of the family of probes powered by the CYCLO G6™ Glaucoma L...
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.